Lineage Cell Therapeutics (LCTX) Income towards Parent Company (2010 - 2026)

Lineage Cell Therapeutics has reported Income towards Parent Company for 17 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 19.26% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$13.8 million (up 23.73% YoY), and the FY2025 full-year result was -$63.4 million, down 241.01% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$7.2 million, down from $16.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was $16.2 million in Q4 2025, with the low at -$19.3 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$5.0 million across 5 years, with a median of -$5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 389.85% — and 2025, when it surged 597.45%.
• Lineage Cell Therapeutics' Income towards Parent Company stood at -$6.4 million in 2022, then rose by 25.9% to -$4.7 million in 2023, then jumped by 31.06% to -$3.2 million in 2024, then surged by 597.45% to $16.2 million in 2025, then slumped by 144.46% to -$7.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$7.2 million (Q1 2026), $16.2 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.